Array Biopharma, Inc. (ARRY) Posts Q4 Loss of 9c/Share, Narrower than Views
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $8.54 +6.75%
Revenue Growth %: -11.6%
Financial Fact:
Total operating expenses: 63.27M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: -11.6%
Financial Fact:
Total operating expenses: 63.27M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Array Biopharma, Inc. (NASDAQ: ARRY) reported Q4 EPS of ($0.09), $0.04 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $20.7 million versus the consensus estimate of $21.45 million.
For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.
For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- C.H. Robinson acquires DeSpir Logistics for $75 million
- Sun Communities names Ileana McAlary as general counsel and EVP
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
